{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:21:03Z","timestamp":1783704063942,"version":"3.55.0"},"reference-count":52,"publisher":"American Society for Clinical Investigation","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,12]]},"abstract":"<jats:p>\n                    CD137 (4-1BB) is a member of the TNFR superfamily that represents a promising target for cancer immunotherapy. Recent insights into the function of TNFR agonist antibodies implicate epitope, affinity, and IgG subclass as critical features, and these observations help explain the limited activity and toxicity seen with clinically tested CD137 agonists. Here, we describe the preclinical characterization of CTX-471, a fully human IgG4 agonist of CD137 that engages a unique epitope that is shared by human, cynomolgus monkey, and mouse and is associated with a differentiated pharmacology and toxicology profile. In vitro, CTX-471 increased IFN-\u03b3 production by human T cells in an Fc\u03b3 receptor\u2013dependent (Fc\u03b3R-dependent) manner, displaying an intermediate level of activity between 2 clinical-stage anti-CD137 antibodies. In mice, CTX-471 exhibited curative monotherapy activity in various syngeneic tumor models and showed a unique ability to cure mice of very large (~500 mm\n                    <jats:sup>3<\/jats:sup>\n                    ) tumors compared with validated antibodies against checkpoints and TNFR superfamily members. Extremely high doses of CTX-471 were well tolerated, with no signs of hepatic toxicity. Collectively, these data demonstrate that CTX-471 is a unique CD137 agonist that displays an excellent safety profile and an unprecedented level of monotherapy efficacy against very large tumors.\n                  <\/jats:p>","DOI":"10.1172\/jci.insight.133647","type":"journal-article","created":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T11:01:43Z","timestamp":1583924503000},"source":"Crossref","is-referenced-by-count":38,"title":["Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity"],"prefix":"10.1172","volume":"5","author":[{"given":"Ugur","family":"Eskiocak","sequence":"first","affiliation":[{"name":"Compass Therapeutics, Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Guzman","sequence":"additional","affiliation":[{"name":"Compass Therapeutics, Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Wolf","sequence":"additional","affiliation":[{"name":"Compass Therapeutics, Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Cummings","sequence":"additional","affiliation":[{"name":"Compass Therapeutics, Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Milling","sequence":"additional","affiliation":[{"name":"Compass Therapeutics, Cambridge, Massachusetts, USA."},{"name":"Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Jung","family":"Wu","sequence":"additional","affiliation":[{"name":"Compass Therapeutics, Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ophir","sequence":"additional","affiliation":[{"name":"Compass Therapeutics, Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conner","family":"Lambden","sequence":"additional","affiliation":[{"name":"Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Harvard Medical School and Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0984-2453","authenticated-orcid":true,"given":"Pearl","family":"Bakhru","sequence":"additional","affiliation":[{"name":"Compass Therapeutics, Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana C.","family":"Gilmore","sequence":"additional","affiliation":[{"name":"Compass Therapeutics, Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Ottinger","sequence":"additional","affiliation":[{"name":"Compass Therapeutics, Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Liu","sequence":"additional","affiliation":[{"name":"Compass Therapeutics, Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William K.","family":"McConaughy","sequence":"additional","affiliation":[{"name":"Compass Therapeutics, Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunny Q.","family":"He","sequence":"additional","affiliation":[{"name":"Compass Therapeutics, Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[{"name":"Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Harvard Medical School and Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheuk Lun","family":"Leung","sequence":"additional","affiliation":[{"name":"Compass Therapeutics, Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Lajoie","sequence":"additional","affiliation":[{"name":"Compass Therapeutics, Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"IV","given":"William F.","family":"Carson","sequence":"additional","affiliation":[{"name":"Compass Therapeutics, Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Zizlsperger","sequence":"additional","affiliation":[{"name":"Compass Therapeutics, Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Compass Therapeutics, Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Harvard Medical School and Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Bobrowicz","sequence":"additional","affiliation":[{"name":"Compass Therapeutics, Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Schuetz","sequence":"additional","affiliation":[{"name":"Compass Therapeutics, Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Tighe","sequence":"additional","affiliation":[{"name":"Compass Therapeutics, Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"232","published-online":{"date-parts":[[2020,3,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.75"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.09.026"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.97"},{"issue":"18","key":"B4","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121322","article-title":"4-1BB enhancement of CAR T function requires NF-\u03baB and TRAFs","volume":"3","author":"Li","year":"2018","journal-title":"JCI Insight"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nm0697-682"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0677"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-223958"},{"key":"B8","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2015.00117","article-title":"4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity","volume":"5","author":"Bartkowiak","year":"2015","journal-title":"Front Oncol"},{"issue":"7","key":"B9","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1599636","article-title":"Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells","volume":"8","author":"Ochoa","year":"2019","journal-title":"Oncoimmunology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0200664"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0879"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0118"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nm1405"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1272"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1922"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07136-7"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1084\/jem.186.1.47"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1847"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.7.4194"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10088-1"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.02.009"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.05.001"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.09.014"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.757773"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2018.02.006"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12349"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aao4910"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1997.8016"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0767"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20171068"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.11.014"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.08.052"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2017.1323159"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1200356"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2014.06.013"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.08.004"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.03.013"},{"key":"B38","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14572","article-title":"Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice","volume":"8","author":"Lau","year":"2017","journal-title":"Nat Commun"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0013"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206223"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0945"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.4132\/jptm.2015.06.01"},{"issue":"6","key":"B43","first-page":"6656","article-title":"The role of tumor-associated macrophages in breast carcinoma invasion and metastasis","volume":"8","author":"Yang","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat1500"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1700407"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1172\/JCI80445"},{"issue":"8","key":"B47","article-title":"TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM","volume":"7","author":"Hung","year":"2018","journal-title":"Oncoimmunology"},{"key":"B48","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02216","article-title":"CD137L-DCs, Potent Immune-Stimulators-History, Characteristics, and Perspectives","volume":"10","author":"Zeng","year":"2019","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016129"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401383"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.4110\/in.2015.15.3.121"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0846-9"}],"container-title":["JCI Insight"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/insight.jci.org\/articles\/view\/133647\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:17:28Z","timestamp":1779193048000},"score":1,"resource":{"primary":{"URL":"https:\/\/insight.jci.org\/articles\/view\/133647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,12]]},"references-count":52,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,3,12]]},"published-print":{"date-parts":[[2020,3,12]]}},"alternative-id":["10.1172\/jci.insight.133647"],"URL":"https:\/\/doi.org\/10.1172\/jci.insight.133647","relation":{},"ISSN":["2379-3708"],"issn-type":[{"value":"2379-3708","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,12]]},"article-number":"e133647"}}